Carollo et al., 2016 - Google Patents
Lutetium-177 labeled peptides: the European Institute of oncology experienceCarollo et al., 2016
- Document ID
- 9918329356304585818
- Author
- Carollo A
- Papi S
- Chinol M
- Publication year
- Publication venue
- Current Radiopharmaceuticals
External Links
Snippet
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogues has shown encouraging results in various somatostatin receptor positive tumors. Partial remission rates up to 30% have been documented as well as significant improvements in …
- 102000004196 processed proteins & peptides 0 title abstract description 17
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G4/00—Radioactive sources
- G21G4/04—Radioactive sources other than neutron sources
- G21G4/06—Radioactive sources other than neutron sources characterised by constructional features
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/0005—Isotope delivery systems
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
- G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
- G21G1/001—Recovery of specific isotopes from irradiated targets
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21F—PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
- G21F1/00—Shielding characterised by the composition of the materials
- G21F1/02—Selection of uniform shielding materials
- G21F1/06—Ceramics; Glasses; Refractories
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chandra et al. | Nuclear medicine physics: the basics | |
| NO310544B1 (en) | Preparation and use of radium-223 for the preparation of preparations and kits for the treatment of calcified tissue for palliation, bone cancer therapy and / or bone surface treatment | |
| US20210379212A1 (en) | Stable, concentrated radionuclide complex solutions | |
| Bal et al. | Pharmacokinetic, Dosimetry and Toxicity Study of; 177Lu-EDTMP in Patients: Phase 0/I study | |
| WO2020021310A1 (en) | Stable, concentrated radionuclide complex solutions | |
| Dahle et al. | Relative biologic effects of low-dose-rate α-emitting 227Th-rituximab and β-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation | |
| Lange et al. | Radiopharmaceuticals | |
| Carollo et al. | Lutetium-177 labeled peptides: the European Institute of oncology experience | |
| US20210130253A1 (en) | Purification method | |
| Safarzadeh et al. | Production, Radiolabeling and Biodistribution Studies of 175Yb-DOTMP as Bone Pain Palliation: 175Yb-DOTMP as bone pain palliation | |
| Kim et al. | Radiation dose assessment for radiation workers during 18F-FDG synthesis and dispensing activities in hot cells: a proposal to improve the safety of radiation protection measures for workers | |
| Schwarz et al. | Radiochemistry and radiopharmacology | |
| Mukherjee et al. | Development of semiautomated module for preparation of 131I labeled lipiodol for liver cancer therapy | |
| Towson | Radiation dosimetry and protection in PET | |
| Varghese et al. | Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy | |
| Coura-Filho et al. | Basic Principles of Radiopharmaceuticals | |
| US20240249856A1 (en) | Systems for radioisotope generation and methods of preparation and administration | |
| Favaretto | Development of terbium radioisotopes towards clinical theragnostics applications in nucelar medicine | |
| Sarkodie | Assessment of the Quality and Suitability of Radiopharmaceutical Cold Kits and 99Mo/99mTc Generator Used at the Nuclear Medicine Unit, Korle-Bu Teaching Hospital, Accra | |
| Hassanpour et al. | Effect of Eluting the 99 Mo/99 m Tc Generator More than Once in 24 h on the Efficiency of the 99 m Tc-MIBI Complex | |
| Sen | Nuclear Medicine As Radionuclide in Radiopharmaceutical in Scintigraphy | |
| Luminari et al. | of Lymphomas | |
| Strane | Radium Ra 223 Alpha Therapy for Prostate Cancer Bone Metastasis | |
| Vagahasiya et al. | RADIOPHARMACEUTICAL IN NUCLEAR PHARMACY & MEDICINE AND THEIR THERAPEUTICS APPLICATION IN HEALTH CARE SYSTEM | |
| Evangelista et al. | The bone pathway: 223Ra-dichloride |